Description
HEPAN-L INJ | L-Ornithine L-Aspartate 5gm Injection
Hepan-L Inj is an L-Ornithine L-Aspartate 5gm injection by Arrowin Pharmaceuticals, used in the management of hyperammonaemia and hepatic encephalopathy in patients dealing with acute and chronic liver disease. Hepatologists, gastroenterologists, and physicians managing liver conditions prescribe it regularly to reduce elevated ammonia levels and protect neurological function during liver-related illness.
When the liver is healthy, it clears ammonia efficiently as part of normal metabolism. But in patients with liver disease, whether it is cirrhosis, chronic hepatitis or fatty liver, this clearing capacity breaks down. Ammonia builds up in the blood, crosses into the brain and starts causing problems ranging from mild confusion and disturbed sleep to serious cognitive decline. This is what hepatic encephalopathy looks like in practice, and it is one of the more dangerous complications physicians managing liver disease have to deal with.
L-Ornithine L-Aspartate Injection works by providing the body with two distinct pathways to clear excess ammonia. Ornithine supports the urea cycle in liver cells, helping convert ammonia into urea that the kidneys can then excrete. Aspartate works through a separate route involving glutamine synthesis, which removes ammonia from circulation in both liver and muscle tissue. Having both pathways active simultaneously is what makes this molecule effective, even in patients with significantly reduced liver function.
Beyond ammonia management, Hepan-L Inj also supports liver cell energy metabolism and has shown benefit as adjunctive therapy in non-alcoholic fatty liver disease. The injectable formulation ensures rapid systemic availability, which is critical in acute settings where oral intake may be unreliable or ammonia levels need to come down quickly.
Composition
Each ampoule contains L-Ornithine L-Aspartate 5gm.
Therapeutic Class
Hepatoprotective and Ammonia-Lowering Agent.
Indications
Hepan-L Inj is indicated for hyperammonaemia and hepatic encephalopathy in acute and chronic liver disease, liver cirrhosis with associated cognitive impairment, subclinical and overt encephalopathy, and as adjunctive therapy in non-alcoholic fatty liver disease where elevated ammonia is a contributing factor.
Are There Any Side Effects of Hepan-L Inj?
Hepan-L Inj is generally well tolerated at the recommended infusion rate. The most commonly reported side effects are nausea and vomiting, which occur primarily when the infusion is administered too rapidly and typically resolve by slowing the infusion rate. Mild gastrointestinal discomfort or diarrhoea may occur in some patients, but is usually transient.
Hepan-L Inj should be used with caution in patients with significant renal impairment, as metabolic byproducts are renally excreted. Serum ammonia levels and renal function should be monitored during therapy. Administration should always be under the supervision of a qualified physician.
Packaging
As per standard pharmaceutical ampoule packaging.
FAQs
What is Hepan-L Inj used for?
Hepan-L Inj is an L-Ornithine L-Aspartate injection used to reduce elevated blood ammonia levels in patients with liver disease. It is primarily indicated for hyperammonaemia and hepatic encephalopathy associated with cirrhosis, chronic hepatitis and acute liver failure, and is also used as adjunctive therapy in non-alcoholic fatty liver disease.
How does L-Ornithine L-Aspartate Injection reduce ammonia levels?
L-Ornithine L-Aspartate Injection works through two pathways simultaneously. Ornithine activates the urea cycle in liver cells, promoting the conversion of ammonia to urea for excretion through the kidneys. Aspartate stimulates glutamine synthesis in both liver and muscle tissue, providing an alternative detoxification route. This dual mechanism makes it effective even when liver function is significantly compromised.
Why is the injectable form used instead of oral LOLA?
The injectable formulation of L-Ornithine L-Aspartate is used when a rapid reduction in blood ammonia levels is needed, when the patient’s clinical condition precludes reliable oral intake, or when gut absorption is impaired due to liver disease complications. It delivers the drug directly into systemic circulation, providing faster and more predictable bioavailability than the oral form in acute settings.
Can Hepan-L Inj be used in patients with kidney disease?
Caution is advised in patients with significant renal impairment, as the metabolic byproducts of L-Ornithine L-Aspartate are cleared renally. Renal function should be monitored during therapy, and dose adjustments should be considered based on creatinine levels and clinical response. The treating physician should assess the risk-benefit balance in such patients before initiating therapy.
Is Hepan-L Inj available for PCD Pharma Franchise?
Yes! Hepan-L Inj is available for PCD distribution with monopoly rights across territories. Contact Arrowin Pharmaceuticals to discuss franchise opportunities in your region.
